ACS Fall 2024 First Time Disclosures

The 2024 EFMC-ISMC joint conference in Rome was centered around two first time disclosure sessions which revealed the structures and discovery stories of seven drugs covering a range of hot targets and modalities. This article captures the key highlights from the sessions, detailing the structures and targets of the novel molecules presented, including Novartis’ HIF-2α inhibitor and their folate receptor-targeted RLT, as well as the novel chemical matter of AstraZeneca/Mitsubishi Tanabe’s NLRP3 inflammasome inhibitor and a first-in-class MKK4 inhibitor for liver regeneration.

The "New Drugs on the Horizon" sessions at the AACR Annual Meeting 2024 in San Diego revealed twelve innovative oncology agents and offered attendees a first look at their structures and preliminary data as they enter/progress in the clinic. In case you missed any of these exciting compounds – including selective CDK inhibitors, molecular glues, bifunctional degraders, a radiopharmaceutical, a bifunctional antibody, and an ADC – this article covers the structures and targets disclosed. A separate session disclosed the structure of a pan-RAS isoform inhibitor with remarkable clinical results.

The highly anticipated First Time Disclosures session at the ACS Spring 2024 Meeting in New Orleans, organized by Nicole Goodwin and H. Rachel Lagiakos, presented a variety of new orally available small molecules. In case you missed any of these exciting molecules, from Oric’s CD73 inhibitor to Deciphera’s first-in-class ULK1/2 inhibitor, this article provides the structures and targets for the novel molecules disclosed at the session.